330 related articles for article (PubMed ID: 22720732)
1. Immunogenicity when utilizing adenovirus serotype 4 and 5 vaccines expressing circumsporozoite protein in naïve and adenovirus (Ad5) immune mice.
Schuldt NJ; Aldhamen YA; Godbehere-Roosa S; Seregin SS; Kousa YA; Amalfitano A
Malar J; 2012 Jun; 11():209. PubMed ID: 22720732
[TBL] [Abstract][Full Text] [Related]
2. DNA prime/Adenovirus boost malaria vaccine encoding P. falciparum CSP and AMA1 induces sterile protection associated with cell-mediated immunity.
Chuang I; Sedegah M; Cicatelli S; Spring M; Polhemus M; Tamminga C; Patterson N; Guerrero M; Bennett JW; McGrath S; Ganeshan H; Belmonte M; Farooq F; Abot E; Banania JG; Huang J; Newcomer R; Rein L; Litilit D; Richie NO; Wood C; Murphy J; Sauerwein R; Hermsen CC; McCoy AJ; Kamau E; Cummings J; Komisar J; Sutamihardja A; Shi M; Epstein JE; Maiolatesi S; Tosh D; Limbach K; Angov E; Bergmann-Leitner E; Bruder JT; Doolan DL; King CR; Carucci D; Dutta S; Soisson L; Diggs C; Hollingdale MR; Ockenhouse CF; Richie TL
PLoS One; 2013; 8(2):e55571. PubMed ID: 23457473
[TBL] [Abstract][Full Text] [Related]
3. A three-antigen Plasmodium falciparum DNA prime-Adenovirus boost malaria vaccine regimen is superior to a two-antigen regimen and protects against controlled human malaria infection in healthy malaria-naïve adults.
Sklar MJ; Maiolatesi S; Patterson N; Sedegah M; Limbach K; Teneza-Mora N; Chuang I; Hollis-Perry KM; Banania JG; Guzman I; Ganeshan H; Reyes S; Hollingdale MR; Wong M; Lindstrom A; Reyes A; Alcorta Y; Garver L; Bankard K; Belmonte A; Belmonte M; Huang J; Gowda K; Inoue S; Velasco R; Bergmann-Leitner E; Hutter J; Lee T; Adams N; Chaudhury S; Hunt D; Tamminga C; Berrie E; Bellamy D; Bittaye M; Ewer K; Diggs C; Soisson LA; Lawrie A; Hill A; Richie TL; Villasante E; Epstein JE; Duplessis CA
PLoS One; 2021; 16(9):e0256980. PubMed ID: 34495988
[TBL] [Abstract][Full Text] [Related]
4.
Daniel S; Pichugin A; Torano H; Renn JP; Kwan J; Cowles MV; Conteh S; Lambert LE; Alani N; MacDonald NJ; Dai W; Highsmith K; Anderson C; Gorres JP; Musgrove J; Butler B; Althubaiti N; Dixit S; Zarling-Bejma S; Krzych U; Duffy PE
Infect Immun; 2021 Oct; 89(11):e0016521. PubMed ID: 34310889
[TBL] [Abstract][Full Text] [Related]
5. Adenovirus 5-vectored P. falciparum vaccine expressing CSP and AMA1. Part A: safety and immunogenicity in seronegative adults.
Sedegah M; Tamminga C; McGrath S; House B; Ganeshan H; Lejano J; Abot E; Banania GJ; Sayo R; Farooq F; Belmonte M; Manohar N; Richie NO; Wood C; Long CA; Regis D; Williams FT; Shi M; Chuang I; Spring M; Epstein JE; Mendoza-Silveiras J; Limbach K; Patterson NB; Bruder JT; Doolan DL; King CR; Soisson L; Diggs C; Carucci D; Dutta S; Hollingdale MR; Ockenhouse CF; Richie TL
PLoS One; 2011; 6(10):e24586. PubMed ID: 22003383
[TBL] [Abstract][Full Text] [Related]
6. The Th1 immune response to Plasmodium falciparum circumsporozoite protein is boosted by adenovirus vectors 35 and 26 with a homologous insert.
Radosevic K; Rodriguez A; Lemckert AA; van der Meer M; Gillissen G; Warnar C; von Eyben R; Pau MG; Goudsmit J
Clin Vaccine Immunol; 2010 Nov; 17(11):1687-94. PubMed ID: 20826614
[TBL] [Abstract][Full Text] [Related]
7. Human adenovirus 5-vectored Plasmodium falciparum NMRC-M3V-Ad-PfCA vaccine encoding CSP and AMA1 is safe, well-tolerated and immunogenic but does not protect against controlled human malaria infection.
Tamminga C; Sedegah M; Maiolatesi S; Fedders C; Reyes S; Reyes A; Vasquez C; Alcorta Y; Chuang I; Spring M; Kavanaugh M; Ganeshan H; Huang J; Belmonte M; Abot E; Belmonte A; Banania J; Farooq F; Murphy J; Komisar J; Richie NO; Bennett J; Limbach K; Patterson NB; Bruder JT; Shi M; Miller E; Dutta S; Diggs C; Soisson LA; Hollingdale MR; Epstein JE; Richie TL
Hum Vaccin Immunother; 2013 Oct; 9(10):2165-77. PubMed ID: 23899517
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity and protection of a recombinant human adenovirus serotype 35-based malaria vaccine against Plasmodium yoelii in mice.
Ophorst OJ; Radosević K; Havenga MJ; Pau MG; Holterman L; Berkhout B; Goudsmit J; Tsuji M
Infect Immun; 2006 Jan; 74(1):313-20. PubMed ID: 16368986
[TBL] [Abstract][Full Text] [Related]
9. Heterologous prime-boost regimen adenovector 35-circumsporozoite protein vaccine/recombinant Bacillus Calmette-Guérin expressing the Plasmodium falciparum circumsporozoite induces enhanced long-term memory immunity in BALB/c mice.
Arama C; Assefaw-Redda Y; Rodriguez A; Fernández C; Corradin G; Kaufmann SH; Reece ST; Troye-Blomberg M
Vaccine; 2012 Jun; 30(27):4040-5. PubMed ID: 22521849
[TBL] [Abstract][Full Text] [Related]
10. Controlled Human Malaria Infection (CHMI) differentially affects cell-mediated and antibody responses to CSP and AMA1 induced by adenovirus vaccines with and without DNA-priming.
Sedegah M; Hollingdale MR; Farooq F; Ganeshan H; Belmonte M; Huang J; Abot E; Limbach K; Chuang I; Tamminga C; Epstein JE; Villasante E
Hum Vaccin Immunother; 2015; 11(11):2705-15. PubMed ID: 26292027
[TBL] [Abstract][Full Text] [Related]
11. Liver-Directed AAV8 Booster Vaccine Expressing
Shahnaij M; Iyori M; Mizukami H; Kajino M; Yamagoshi I; Syafira I; Yusuf Y; Fujiwara K; Yamamoto DS; Kato H; Ohno N; Yoshida S
Front Immunol; 2021; 12():612910. PubMed ID: 34248928
[TBL] [Abstract][Full Text] [Related]
12. A prime-boost immunization regimen based on a simian adenovirus 36 vectored multi-stage malaria vaccine induces protective immunity in mice.
Fonseca JA; McCaffery JN; Kashentseva E; Singh B; Dmitriev IP; Curiel DT; Moreno A
Vaccine; 2017 May; 35(24):3239-3248. PubMed ID: 28483199
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of a prime-boost vaccine schedule with distinct adenovirus vectors against malaria in rhesus monkeys.
Rodríguez A; Mintardjo R; Tax D; Gillissen G; Custers J; Pau MG; Klap J; Santra S; Balachandran H; Letvin NL; Goudsmit J; Radosević K
Vaccine; 2009 Oct; 27(44):6226-33. PubMed ID: 19686691
[TBL] [Abstract][Full Text] [Related]
14. Adenovirus-5-vectored P. falciparum vaccine expressing CSP and AMA1. Part B: safety, immunogenicity and protective efficacy of the CSP component.
Tamminga C; Sedegah M; Regis D; Chuang I; Epstein JE; Spring M; Mendoza-Silveiras J; McGrath S; Maiolatesi S; Reyes S; Steinbeiss V; Fedders C; Smith K; House B; Ganeshan H; Lejano J; Abot E; Banania GJ; Sayo R; Farooq F; Belmonte M; Murphy J; Komisar J; Williams J; Shi M; Brambilla D; Manohar N; Richie NO; Wood C; Limbach K; Patterson NB; Bruder JT; Doolan DL; King CR; Diggs C; Soisson L; Carucci D; Levine G; Dutta S; Hollingdale MR; Ockenhouse CF; Richie TL
PLoS One; 2011; 6(10):e25868. PubMed ID: 22003411
[TBL] [Abstract][Full Text] [Related]
15. Sterile immunity to malaria after DNA prime/adenovirus boost immunization is associated with effector memory CD8+T cells targeting AMA1 class I epitopes.
Sedegah M; Hollingdale MR; Farooq F; Ganeshan H; Belmonte M; Kim Y; Peters B; Sette A; Huang J; McGrath S; Abot E; Limbach K; Shi M; Soisson L; Diggs C; Chuang I; Tamminga C; Epstein JE; Villasante E; Richie TL
PLoS One; 2014; 9(9):e106241. PubMed ID: 25211344
[TBL] [Abstract][Full Text] [Related]
16. A Recombinant Chimeric Ad5/3 Vector Expressing a Multistage Plasmodium Antigen Induces Protective Immunity in Mice Using Heterologous Prime-Boost Immunization Regimens.
Cabrera-Mora M; Fonseca JA; Singh B; Zhao C; Makarova N; Dmitriev I; Curiel DT; Blackwell J; Moreno A
J Immunol; 2016 Oct; 197(7):2748-61. PubMed ID: 27574299
[TBL] [Abstract][Full Text] [Related]
17. Prime-boost vectored malaria vaccines: progress and prospects.
Hill AV; Reyes-Sandoval A; O'Hara G; Ewer K; Lawrie A; Goodman A; Nicosia A; Folgori A; Colloca S; Cortese R; Gilbert SC; Draper SJ
Hum Vaccin; 2010 Jan; 6(1):78-83. PubMed ID: 20061802
[TBL] [Abstract][Full Text] [Related]
18. Sterile protection against Plasmodium knowlesi in rhesus monkeys from a malaria vaccine: comparison of heterologous prime boost strategies.
Jiang G; Shi M; Conteh S; Richie N; Banania G; Geneshan H; Valencia A; Singh P; Aguiar J; Limbach K; Kamrud KI; Rayner J; Smith J; Bruder JT; King CR; Tsuboi T; Takeo S; Endo Y; Doolan DL; Richie TL; Weiss WR
PLoS One; 2009 Aug; 4(8):e6559. PubMed ID: 19668343
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity.
Barouch DH; Pau MG; Custers JH; Koudstaal W; Kostense S; Havenga MJ; Truitt DM; Sumida SM; Kishko MG; Arthur JC; Korioth-Schmitz B; Newberg MH; Gorgone DA; Lifton MA; Panicali DL; Nabel GJ; Letvin NL; Goudsmit J
J Immunol; 2004 May; 172(10):6290-7. PubMed ID: 15128818
[TBL] [Abstract][Full Text] [Related]
20. Importance of the Immunodominant CD8
Gibbins MP; Müller K; Glover M; Liu J; Putrianti ED; Bauza K; Reyes-Sandoval A; Matuschewski K; Silvie O; Hafalla JCR
Infect Immun; 2020 Sep; 88(10):. PubMed ID: 32719159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
